Celldex Therapeutics
CLDX
157 hedge funds and large institutions have $1.38B invested in Celldex Therapeutics in 2014 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 60 increasing their positions, 50 reducing their positions, and 26 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 50
3% less funds holding
Funds holding: 162 → 157 (-5)
12% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 26
25% less capital invested
Capital invested by funds: $1.85B → $1.38B (-$470M)
28% less call options, than puts
Call options by funds: $20.4M | Put options by funds: $28.5M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
+$51.7M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$49.9M |
| 3 |
O
OrbiMed
New York
|
+$26.5M |
| 4 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$25.6M |
| 5 |
AC
Apex Capital
Orinda,
California
|
+$13.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$43.1M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$20.9M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$13.9M |
| 4 |
Jennison Associates
New York
|
-$12.6M |
| 5 |
CCI
Columbus Circle Investors
|
-$10.8M |
CLDX Hedge Fund Activity: Q1 2014 in Review
157 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2014, worth a combined $1.38B — down 25% from $1.85B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CLDX and 23 opened new positions — a net loss of 3 holders — while 50 trimmed existing stakes and 60 added.
The largest buyer was OppenheimerFunds, adding an estimated $51.7M. The largest seller was SAC Capital Advisors, cutting an estimated $43.1M.
- 157 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2014, down from 162 in Q4 2013.
- Funds reported $1.38B of Celldex Therapeutics stock for Q1 2014, down 25% quarter-over-quarter.
- 23 funds opened new Celldex Therapeutics positions in Q1 2014 and 26 closed out, a net change of -3 holders.
- The largest Celldex Therapeutics buyer in Q1 2014 was OppenheimerFunds, an estimated $51.7M added.
- The largest Celldex Therapeutics seller in Q1 2014 was SAC Capital Advisors, an estimated $43.1M sold.
Based on aggregated 13F filings for Q1 2014.